Search This Blog

Thursday, March 19, 2026

Rothschild ups MoonLake Immunotherapeutics to Buy, raises price target to $40 from $12

 


  • Firm cites increased clarity on regulatory pathway for sonelokimab in hidradenitis suppurativa as key driver.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)